Drug Pricing Hospitals Pharmaceutical Manufacturing 
Proxsys Rx
APRIL 1, 2025
Maximizing pharmacys role in your hospitals revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. Recent estimates indicate that hospitals and clinics collectively lose around $3.2
Drug Channels
MAY 20, 2025
Topics will include: The competitive landscape of retail pharmacy , with exclusive market data from DCI and 46brooklyn Key economic trends among leading PBMs and their impact on the market PBMs controversial effect on pharmacy and how theyre shaping the industry The medications driving pharmacy profits and the ones bringing financial pain The benefits (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
MARCH 15, 2022
drug pricing, reimbursement, and dispensing system. The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , our 13th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. The chart below illustrates the depth and breadth of the 2022 edition.
Drug Channels
MARCH 18, 2025
Pharmacies and PBMs, Examining $683 Billion Market Review pricing/license options and download the full 2025 report Order before March 31, 2025 to receive special discounted pricing! drug pricing, reimbursement, and dispensing system. prescription drug channels. What's inside?
Proxsys Rx
JANUARY 10, 2023
Nobody’s ever put it better than the Association of American Medical Colleges (AAMC): “Congress created the 340B Drug Pricing Program in 1992 to protect safety-net hospitals from escalating drug prices by allowing them to purchase outpatient drugs at a discount from manufacturers. percent to 3.5
Proxsys Rx
OCTOBER 6, 2022
Why specialized software is essential for successful 340B programs As we’ve mentioned in several previous posts, many hospitals taking full advantage of 340B programs’ discounts save millions of dollars a year on prescription costs. Once TPAs have 340B prices, we order the eligible drugs for those 340B programs.
Viseven
JANUARY 13, 2023
So, at the end of the day, the HEOR’s major task is to make sure that the patients who get access to the new treatment will get the best health outcomes at the most affordable price. HEOR Impact on Drug Pricing and Marketing. Healthcare Institutions – public or private hospitals, healthcare providers, medical centers.
Expert insights. Personalized for you.
52 
Let's personalize your content